MYUNGMOON Pharm co.,Ltd

KOSE:A017180 Stock Report

Market Cap: ₩69.9b

MYUNGMOON PharmLtd Valuation

Is A017180 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A017180 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A017180's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A017180's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A017180?

Other financial metrics that can be useful for relative valuation.

A017180 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA30x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A017180's PS Ratio compare to its peers?

The above table shows the PS ratio for A017180 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
A014570 Korean Drug
0.8xn/a₩67.8b
A000220 Yuyu Pharma
0.6xn/a₩76.5b
A044960 Eagle Veterinary TechnologyLtd
1.5xn/a₩66.1b
A260660 Korea Arlico PharmLtd
0.4xn/a₩78.8b
A017180 MYUNGMOON PharmLtd
0.4xn/a₩69.9b

Price-To-Sales vs Peers: A017180 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.8x).


Price to Earnings Ratio vs Industry

How does A017180's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.2%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.2%
n/an/an/a
No more companies

Price-To-Sales vs Industry: A017180 is good value based on its Price-To-Sales Ratio (0.4x) compared to the KR Pharmaceuticals industry average (0.9x).


Price to Sales Ratio vs Fair Ratio

What is A017180's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A017180 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A017180's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.